Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors.
To date, lung cancer is the leading cause of cancer-related death worldwide, among which nonsmall cell lung cancer (NSCLC) comprises about 85%. Taking into account the side effects of surgery, radiation, platinum-based doublet chemotherapy, and the growth self-sufficiency characteristic of cancer cells, drugs have been discovered toward growth factor receptor (GFR) to treat NSCLC. As expected, these drugs provide a greater benefit. To increase the efficacy of such growth factor receptor tyrosine kinase inhibitors (RTKIs), coinhibition of GFR signaling pathways and combination of inhibitors along with radiation or chemotherapy have drew intense insight. Although clinical trials about single-agent RTKIs or their combination strategies suggest their increase potency against cancer, they are not beyond adverse effects, and sometimes the effects are more deadly than chemotherapy. Nevertheless the hope for RTKIs may be proved true by further researches and digging deep into cancer therapeutics.
Molecular Biology Research Center, School of Life Science and State Key Laboratory of Medical Genetics of China, Central South University, Changsha, Hunan 410078, China.
Mridul
M
Roy
Yu-Hao
YH
Luo
Mao
M
Ye
Jing
J
Liu
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D002986:Clinical Trials as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000627:therapeutic use; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D054852:Small Molecule Libraries
D047428:Protein Kinase Inhibitors; D017978:Receptors, Growth Factor; D054852:Small Molecule Libraries; D020794:Receptor Protein-Tyrosine Kinases